Corcoran, MN, United States of America

Tzehaw Chen

This inventor holds 20 USPTO granted patents and 6 published patent applications and 1 EPO patent, primarily in Pharmaceutical Formulations. Top assignees: Nanocopoeia, LLC, Handa Therapeutics, LLC, Flex Pharma, Inc.. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tzehaw Chen. Retrieved from https://idiyas.com/inventor/tzehaw-chen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 20 

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.4

ph-index = 6

Forward Citations = 49(Granted Patents)


Location History:

  • Saint Louis Park, MN (US) (2021)
  • Corcoran, MN (US) (2022 - 2024)
  • Cocoran, MN (US) (2024)

Company Filing History:


Years Active: 2021-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Amorphous Nilotinib
Microparticles
Amorphous Solid Dispersions
Dasatinib
Pharmaceutical Compositions
Crushable Tablets
Orally Disintegrating Tablet
Cabozantinib
Particle Engineering
Drug Delivery
Formulation Science
Bioavailability
20 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Tzehaw Chen

Introduction

Tzehaw Chen is a notable inventor based in Corcoran, MN, who has made significant contributions to the field of pharmaceuticals. With a total of 13 patents to his name, Chen's work primarily focuses on developing innovative drug formulations that enhance the efficacy of cancer treatments.

Latest Patents

Among his latest patents, Chen has developed "Amorphous solid dispersions of dasatinib and uses thereof." This invention involves pharmaceutical compositions of the protein kinase inhibitor dasatinib, which can be utilized in treating proliferative disorders such as cancer. The compositions are designed to be effective regardless of whether the patient is concurrently administered a gastric acid-reducing agent or has an elevated gastric pH. This is particularly beneficial for patients suffering from achlorhydria or hypochlorhydria.

Another significant patent is "Amorphous nilotinib microparticles and uses thereof." This invention focuses on pharmaceutical compositions of nilotinib, another protein kinase inhibitor. These compositions can be administered without regard to food consumption and can be given at a significantly lower dose compared to existing formulations, while still providing a comparable therapeutic effect.

Career Highlights

Tzehaw Chen has worked with several companies throughout his career, including Nanocopoeia, LLC and Handa Therapeutics, LLC. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovations and contribute to the development of effective cancer treatments.

Collaborations

Chen has collaborated with notable professionals in the field, including Christian F Wertz and Joseph McTarsney. These collaborations have further enhanced his research and development efforts, leading to groundbreaking advancements in pharmaceutical formulations.

Conclusion

Tzehaw Chen's innovative work in the pharmaceutical industry has led to significant advancements in cancer treatment formulations. His contributions continue to impact the field positively, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…